The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 3, 2014, Pages 325-336

  Kassim, Adetola A ^a   Debaun, Michael R ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Hematopoietic stem cell transplantation; Hydroxyurea; Regular blood transfusion; Sickle cell disease

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HYDROXYUREA; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ACUTE CHEST SYNDROME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; ASYMPTOMATIC DISEASE; BACTERIAL INFECTION; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE INFERTILITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; IRON STORAGE; MORBIDITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; PRIMARY PREVENTION; REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SURVIVAL TIME; TERATOGENICITY; TRANSCRANIAL DOPPLER;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHEST PAIN; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; MODELS, STATISTICAL; PAIN; STROKE;

EID: 84892692040     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.868435     Document Type: Review

References (72)

1. Osarogiagbon UR, Choong S, Belcher JD, et al. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000;96:314-20
2. Ware RE, Rees RC, Sarnaik SA, et al.; BABY HUG Investigators. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr 2010;156(1):66-70
3. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009;146:300-5
4. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005;84:363-76
5. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003;123:359-65
6. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593-9
7. Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985;107(2):201-6
8. Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006;108:847-52
9. Lee A, Thomas P, Cupidore L, et al. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ 1995;311:1600-2
10. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-9
11. Ammann AJ, Addiego J, Wara DW, et al. Polyvalent pneumococcal polysaccharide immunization of patients with sickle cell anemia and patients with splenectomy. N Engl J Med 1977;297:897
12. Goldblatt D, Johnson M, Evans J. Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. Immunobiology Unit, Institute of Child Health, London. Arch Dis Child 1996;75(2):159-61
13. Armstrong-Wells J, Grimes B, Sidney S, et al. Utilization of TCD screening for primary stroke prevention in children with sickle cell disease. Neurology 2009;72:1316-21
14. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22
15. Lobo CL, Pinto JF, Nascimento EM, et al. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013;161:852-60.
16. Quinn CT, Lee NJ, Shull EP, et al. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood 2008;111:544-8
17. Quinn CT, Shull EP, Ahmad N, et al. Prognostic significance of early vasoocclusive complications in children with sickle cell anemia. Blood 2007;109:40-5
18. Sebastiani P, Nolan VG, Baldwin CT, et al. A network model to predict the risk of death in sickle cell disease. Blood 2007;110:2727-35
19. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001;139:785-9
20. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95:1918-24
21. O'Brien SH, Hankins JS. Decision analysis of treatment strategies in children with severe sickle cell disease. J Pediatr Hematol Oncol 2009;31:873-8
22. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer 2007;48:705-10
23. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-51
24. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-63
25. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009;62-9
26. Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012;120:4304-10; quiz 4448
27. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010;85:403-8.
28. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330(23):1639-44
29. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84:618-25
30. Alvarez O, Yovetich NA, Scott JP, et al.; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH). Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol 2013;88(11):932-8.
31. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-72.
32. Jain DL, Sarathi V, Desai S, et al. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin 2012;36(4):323-32
33. Sharef SW, Al-Hajri M, Beshlawi I, et al. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Eur J Haematol 2013;90(6):519-24
34. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am 2008;55:483-501, x
35. Brandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol 2011;86(9):804-6
36. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J 2007;7:386-94
37. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93:988-93
38. Lanzkron S, Haywood C Jr, Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc 2008;100:968-73
39. Lebensburger JD, Sidonio RF, Debaun MR, et al. Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer 2013;60:1333-7
40. Kovacic P. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses 2011;76:24-31
41. da Silva RLB, Dias EDB, Barbosa MC, et al. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBBS haplotype. Mutat Res 2012;749:48-52
42. Flanagan JM, Howard TA, Mortier N, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 2010;698:38-42
43. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-45
44. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339(1):5-11
45. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol 2001;38:5-13
46. Telen MJ. Principles and problems of transfusion in sickle cell disease. Semin Hematol 2001;38:315-23
47. Serjeant GR. Chronic transfusion programmes in sickle cell disease: problem or panacea? Br J Haematol 1997;97:253-5
48. Vichinsky E. Transfusion-related iron overload in sickle cell anemia. Semin Hematol 2001;38:1-84
49. Inati A, Musallam KM, Wood JC, et al. Absence of cardiac siderosis by MRI T2 despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol 2009;83:565-71
50. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122:1062-71
51. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusiontransmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334(26):1685-90
52. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011;117:772-9.
53. Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000;96:2369-72
54. Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013;2013:370-6
55. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007;137:479-85
56. Mentzer WC, Heller S, Pearle PR, et al. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994;16:27-9
57. Walters MC, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996;2:100-4
58. Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010;16:263-72
59. Bruno B, Souillet G, Bertrand Y, et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant 2004;34:143-7
60. Field JJ, Glassberg J, Gilmore A, et al. Longitudinal analysis of pulmonary function in adults with sickle cell disease. Am J Hematol 2008;83:574-6
61. Field JJ, De Baun MR, Yan Y, et al. Growth of lung function in children with sickle cell anemia. Pediatr Pulmonol 2008;43:1061-6
62. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50
63. Jacobsohn DA, Duerst R, Tse W, et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of nonmalignant diseases in children. Lancet 2004;364:156-62
64. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003;9:519-28
65. Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-17
66. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-7
67. Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007;11(6):641-4
68. Ruggeri A, Eapen M, Scaravadou A, et al.; Eurocord Registry; Center for International Blood and Marrow Transplant Research; New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011;17(9):1375-82
69. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012;18(8):1265-72
70. Locatelli F, Kabbara N, Ruggeri A, et al.; Eurocord and European Blood and Marrow Transplantation (EBMT) group. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013;122(6):1072-8
71. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285-91.
72. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998;22(1):1-6